Targeted Therapy–Immunotherapy Combination for Kidney Cancer
March 19, 2019, by NCI Staff PET scan of a tumor in the right kidney (arrows). Credit: Onco Targets Ther Feb 2014. doi: 10.2147/OTT.S58089. CC-BY 3.0 On April 19, 2019, the Food and Drug Administration approved pembrolizumab (Keytruda) in combination with axitinib (Inlyta) for the initial treatment of people with advanced kidney cancer. The approval … Read more